Abstract
Background
Gastrointestinal (GI) surgery involving gastric resection and bypass of intestinal segments was reported to facilitate glucose control in obese patients with type 2 diabetes (T2D).
Aim
Our aim was to assess whether the type of post-gastrectomy GI reconstruction also influences glucose control in T2D patients with BMI below 35 kg/m2 submitted to gastrointestinal surgery without bariatric intention.
Methods
A cohort of T2D Caucasian patients (n = 40) with upper GI malignancy (n = 33) or complicated reflux disease (n = 7) were submitted to either a gastrectomy plus Billroth II (BII) gastrojejunal anastomosis (n = 17), a gastrectomy plus Roux-en-Y gastrojejunostomy (RY) reconstruction (n = 18; subtotal gastrectomy n = 7 and total gastrectomy n = 11), or atypical gastrectomy without reconstruction (no-R) (n = 5). Patients were evaluated before and 2 years after surgery for body weight, Hb1Ac, need of glucose lowering drugs, and presence of diabetes.
Results
Body mass index (BMI) decreased after every surgical procedure when compared to baseline (− 0.9 ± 0.8 kg/m2 for BII vs − 4.3 ± 2.6 kg/m2 for RY vs − 4.6 ± 2.5 kg/m2 for no-R, p < 0.05), which was only significantly different after RY surgeries. Diabetes remission occurred in 5.9% of BII patients, in 27.8% of RY patients, and 0% of no-R patients, while in patients with persistent T2D, the needs for glucose-lowering drugs were significantly also decreased after RY (31.3% BII vs 66.7% RY vs 25% no-R, p = 0.03).
Conclusions
T2D Caucasian patients undergoing post-gastrectomy GI reconstructions without a bariatric intention experience a significant improvement of T2D, in a magnitude that could be influenced by the technical procedure performed in favor of RY reconstruction. Thus, presence of T2D should be taken into consideration when deciding for the type of post-gastrectomy GI reconstruction.
Similar content being viewed by others
Abbreviations
- BMI:
-
Body weight index
- BII:
-
Billroth II
- GLP-1:
-
Glucagon-like peptide-1
- HbA1c:
-
Glycated hemoglobin A1c
- RY:
-
Roux-en-Y reconstruction
- T2D:
-
Type 2 diabetes
References
Kang, K.C., et al., Influence of gastrectomy for stomach cancer on type 2 diabetes mellitus for patients with a body mass index less than 30 kg/m(2). J Korean Surg Soc, 2012. 82(6): p. 347–55.
Maleckas, A., et al., Surgery in the treatment of type 2 diabetes mellitus. Scand J Surg, 2015. 104(1): p. 40–7.
Nora, M., et al., Metabolic laparoscopic gastric bypass for obese patients with type 2 diabetes. Obes Surg, 2011. 21(11): p. 1643–9.
Lanzarini, E., et al., Evolution of type 2 diabetes mellitus in non morbid obese gastrectomized patients with Roux en-Y reconstruction: retrospective study. World J Surg, 2010. 34(9): p. 2098–102.
Lee, T.H., et al., Long-term Follow-up for Type 2 Diabetes Mellitus after Gastrectomy in Non-morbidly Obese Patients with Gastric Cancer: the Legitimacy of Onco-metabolic Surgery. J Gastric Cancer, 2017. 17(4): p. 283–294.
Wei, Z.W., et al., Impact of pre-existing type-2 diabetes on patient outcomes after radical resection for gastric cancer: a retrospective cohort study. Dig Dis Sci, 2014. 59(5): p. 1017–24.
Scopinaro, N., et al., Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg, 2011. 253(4): p. 699–703.
Seki, Y., et al., The Effects of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass on Japanese Patients with BMI < 35 kg/m(2) on Type 2 Diabetes Mellitus and the Prediction of Successful Glycemic Control. Obes Surg, 2018. 28(8): p. 2429–2438.
Fried, M., et al., Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies. Obes Surg, 2010. 20(6): p. 776–90.
Cummings, D.E. and F. Rubino, Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia, 2018. 61(2): p. 257–264.
Shah, S., et al., Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus. Surg Obes Relat Dis, 2010. 6(2): p. 152–7.
Rubino, F., Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care, 2008. 31 Suppl 2: p. S290–6.
Yska, J.P., et al., Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom. JAMA Surg, 2015. 150(12): p. 1126–33.
Skogar, M.L. and M. Sundbom, Duodenal Switch Is Superior to Gastric Bypass in Patients with Super Obesity when Evaluated with the Bariatric Analysis and Reporting Outcome System (BAROS). Obes Surg, 2017. 27(9): p. 2308–2316.
Friedman, M.N., A.J. Sancetta, and G.J. Magovern, The amelioration of diabetes mellitus following subtotal gastrectomy. Surg Gynecol Obstet, 1955. 100(2): p. 201–4.
Mason, E.E., et al., Optimizing results of gastric bypass. Ann Surg, 1975. 182(4): p. 405–14.
Mason, E.E. and C. Ito, Gastric bypass in obesity. Surg Clin North Am, 1967. 47(6): p. 1345–51.
Pories, W.J., et al., Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg, 1995. 222(3): p. 339–50; discussion 350-2.
Pories, W.J., et al., The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg, 1987. 206(3): p. 316–23.
Pories, W.J., et al., Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr, 1992. 55(2 Suppl): p. 582s–585s.
Pories, W.J., et al., Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg, 1992. 215(6): p. 633–42; discussion 643.
Ferchak, C.V. and L.F. Meneghini, Obesity, bariatric surgery and type 2 diabetes--a systematic review. Diabetes Metab Res Rev, 2004. 20(6): p. 438–45.
Zhu, Z., et al., Clinical course of diabetes after gastrectomy according to type of reconstruction in patients with concurrent gastric cancer and type 2 diabetes. Obes Surg, 2015. 25(4): p. 673–9.
Kim, J.Y., T.K. Ha, and C.W. le Roux, Metabolic effects of gastrectomy with or without omentectomy in gastric cancer. Hepatogastroenterology, 2014. 61(134): p. 1830–4.
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care, 2018. 41(Suppl 1): p. S13-s27.
Garg, S.K., et al., Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab, 2014. 16(2): p. 97–110.
Tseng, C.H. and F.H. Tseng, Diabetes and gastric cancer: the potential links. World J Gastroenterol, 2014. 20(7): p. 1701–11.
Cui, J.F., et al., Gastric bypass surgery in non-obese patients with type 2 diabetes mellitus: a 1-year follow-up of 58 cases in Chinese. Int J Clin Exp Med, 2015. 8(3): p. 4393–8.
Kim, J.W., et al., The effect of long Roux-en-Y gastrojejunostomy in gastric cancer patients with type 2 diabetes and body mass index < 35 kg/m(2): preliminary results. Ann Surg Treat Res, 2015. 88(4): p. 215–21.
Manning, S., A. Pucci, and R.L. Batterham, GLP-1: a mediator of the beneficial metabolic effects of bariatric surgery? Physiology (Bethesda), 2015. 30(1): p. 50–62.
Rodrigues, M.R., et al., Metabolic surgery and intestinal gene expression: Digestive tract and diabetes evolution considerations. World J Gastroenterol, 2015. 21(22): p. 6990–8.
Cho, Y.M., A gut feeling to cure diabetes: potential mechanisms of diabetes remission after bariatric surgery. Diabetes Metab J, 2014. 38(6): p. 406–15.
Vetter, M.L., et al., Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and Mechanisms. Diabetes Spectr, 2012. 25(4): p. 200–210.
Fruhbeck, G., Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol, 2015. 11(8): p. 465–77.
Choi, Y.Y., S.H. Noh, and J.Y. An, A randomized controlled trial of Roux-en-Y gastrojejunostomy vs. gastroduodenostomy with respect to the improvement of type 2 diabetes mellitus after distal gastrectomy in gastric cancer patients. 2017. 12(12): p. e0188904.
Li, Q., et al., Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index < 35 kg/m2. Diabetes Obes Metab, 2012. 14(3): p. 262–70.
Batterham, R.L. and D.E. Cummings, Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. Diabetes Care, 2016. 39(6): p. 893–901.
Cordera, R. and G.F. Adami, From bariatric to metabolic surgery: Looking for a “disease modifier” surgery for type 2 diabetes. World J Diabetes, 2016. 7(2): p. 27–33.
Patricio, B.G., et al., Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. 2018.
Palha, A.M., et al., Differential GIP/GLP-1 intestinal cell distribution in diabetics’ yields distinctive rearrangements depending on Roux-en-Y biliopancreatic limb length. 2018.
Ghiassi, S., et al., Conversion of standard Roux-en-Y gastric bypass to distal bypass for weight loss failure and metabolic syndrome: 3-year follow-up and evolution of technique to reduce nutritional complications. Surg Obes Relat Dis, 2018. 14(5): p. 554–561.
Nora, M., et al., Should Roux-en-Y gastric bypass biliopancreatic limb length be tailored to achieve improved diabetes outcomes? Medicine (Baltimore), 2017. 96(48): p. e8859.
Guedes, T.P., et al., Detailed characterization of incretin cell distribution along the human small intestine. Surg Obes Relat Dis, 2015. 11(6): p. 1323–31.
So, J.B., et al., Roux-en-Y or Billroth II Reconstruction After Radical Distal Gastrectomy for Gastric Cancer: A Multicenter Randomized Controlled Trial. Ann Surg, 2018. 267: p. 236–242.
Pak, J., et al., Impact of gastrointestinal bypass on nonmorbidly obese type 2 diabetes mellitus patients after gastrectomy. Surg Obes Relat Dis, 2015. 11(6): p. 1266–72.
Shen, Z., et al., Glycemic changes after gastrectomy in non-morbidly obese patients with gastric cancer and diabetes. Hepatogastroenterology, 2015. 62(137): p. 245–50.
Lovegrove, J.A., CVD risk in South Asians: the importance of defining adiposity and influence of dietary polyunsaturated fat. Proc Nutr Soc, 2007. 66(2): p. 286–98.
Leao, T., et al., Health Inequalities in Diabetes Mellitus and Hypertension: A Parish Level Study in the Northern Region of Portugal. Acta Med Port, 2016. 29(10): p. 605–612.
Morais, S., et al., Trends in gastric cancer mortality and in the prevalence of Helicobacter pylori infection in Portugal. Eur J Cancer Prev, 2016. 25(4): p. 275–81.
Author information
Authors and Affiliations
Contributions
Mariana Costa was responsible for the data acquisition and by writing the manuscript; Marta Guimarães was responsible for the conception of the work and revising it critically; Mário Nora and Mariana P. Monteiro were responsible for drafting the work and revising it critically; Tiago Morais was responsible for analysis and interpretation of data; Trovão Lima, Rui Almeida, Marta Guimarães, and Mário Nora were the surgeons responsible for performing all surgical procedures
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Supplementary Figure S1
–Duration of follow-up (time since surgery in years) for each type of surgical procedure. (PDF 89 kb)
Supplementary Figure S2
– Percentage of patients with diabetes remission vs persistent diabetes (%) submitted either to Partial or Total gastrectomy followed by Roux-en-Y Reconstruction. (PDF 87 kb)
Rights and permissions
About this article
Cite this article
Costa, M., Trovão Lima, A., Morais, T. et al. Does Reconstruction Type After Gastric Resection Matters for Type 2 Diabetes Improvement?. J Gastrointest Surg 24, 1269–1277 (2020). https://doi.org/10.1007/s11605-019-04255-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-019-04255-4